title: [T315I positive promyelocytic crisis of chronic myeloid leukemia].
abstract: Promyelocytic crisis (PMC) of chronic myelogenous leukemia (CML) is relatively rare. We report a patient who progressed to PMC with a T315I mutation during the initial treatment with dasatinib for CML. He obtained hematological remission after combination therapy with all-trans retinoic acid and chemotherapy for PMC, and PML-RARA was not detected by FISH analysis. Arsenic trioxide (ATO) and imatinib therapy induced a second complete cytogenetic response, and PML-RARA mRNA detected by real-time quantitative RT-PCR dropped below the detection limit. Finally, allogeneic stem cell transplantation was performed. This case suggests that combination therapy with imatinib and ATO achieves favorable outcomes for PMC.
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine.
authors: Eri
authors: E
authors: Yamamoto
authors: Etsuko
authors: E
authors: Yamazaki
authors: Yasufumi
authors: Y
authors: Ishiyama
authors: Satoshi
authors: S
authors: Koyama
authors: Yoshimi
authors: Y
authors: Ishii
authors: Yukako
authors: Y
authors: Hattori
authors: Yuki
authors: Y
authors: Nakajima
authors: Takayoshi
authors: T
authors: Tachibana
authors: Takuya
authors: T
authors: Miyazaki
authors: Maki
authors: M
authors: Hagihara
authors: Naoto
authors: N
authors: Tomita
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
mesh_terms: D000328:Adult; D064591:Allografts; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D018450:Disease Progression; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy*; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics / Q000628:therapy*; D008297:Male; D009154:Mutation; D012074:Remission Induction